Next |
home / stock / bbio / bbio message board
Subject | By | Source | When |
---|---|---|---|
Offering comign | Pt3 | investorshub | 03/06/2023 4:47:20 PM |
BridgeBio Announces Positive Phase 2 Cohort 5 Results | 02opida | investorshub | 03/06/2023 4:21:16 PM |
BridgeBio Announces Positive Phase 2 Cohort 5 Results | subslover | investorshub | 03/06/2023 1:34:59 PM |
Recent Trades - Last 10 of 1063 | 02opida | investorshub | 12/08/2022 4:21:10 PM |
volume will start to pickup | 02opida | investorshub | 08/09/2022 6:09:28 PM |
PALO ALTO, Calif., May 13, 2022 (GLOBE NEWSWIRE) | 02opida | investorshub | 08/05/2022 7:27:31 PM |
https://www.stockwatch.com/News/Item/U-z8612485-U!$BBIO-20220804/U/$BBIO | 02opida | investorshub | 08/05/2022 3:45:07 PM |
PALO $ALTO, Calif., May 20, 2022 (GLOBE NEWSWIRE) | 02opida | investorshub | 05/20/2022 12:02:11 PM |
PALO $ALTO, Calif., May 17, 2022 (GLOBE NEWSWIRE) | 02opida | investorshub | 05/17/2022 12:03:22 PM |
BridgeBio Pharma Reports Sale Of Rare Pediatric Disease | crudeoil24 | investorshub | 05/13/2022 11:57:26 AM |
LET'S GO $BBIO > $$$$$ | crudeoil24 | investorshub | 05/12/2022 2:03:55 PM |
BridgeBio Eligible To Receive Up To $905M From | crudeoil24 | investorshub | 05/12/2022 1:52:06 PM |
PALO ALTO and SOLANA BEACH, Calif., March 08, | 02opida | investorshub | 03/08/2022 1:21:24 PM |
NEWS | 02opida | investorshub | 02/24/2022 1:08:09 PM |
PALO ALTO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) | 02opida | investorshub | 01/27/2022 1:01:10 PM |
The Calm before the Storm North | 02opida | investorshub | 01/18/2022 2:01:35 PM |
morning $BBIO | 02opida | investorshub | 01/18/2022 2:00:59 PM |
PALO ALTO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) | 02opida | investorshub | 01/13/2022 1:37:06 PM |
Gap n slap | BigFortune | investorshub | 01/03/2022 1:00:21 PM |
#$BBIO ?? Price dropped 70% & since | da_stock_analyst | investorshub | 01/02/2022 10:52:44 PM |
News, Short Squeeze, Breakout and More Instantly...
BridgeBio Pharma Inc. Company Name:
BBIO Stock Symbol:
NYSE Market:
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biop...
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pres...
- In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (p=0.04), with no safety signals of potential clinical concern - Among ATTRibute-CM part...